Potent inhibition of local and disseminated tumor growth in immunocompetent mouse models by a bispecific antibody construct specific for murine CD3

Cancer Immunology, Immunotherapy

Volumn 55, Issue 7, 2006, Pages 785-796

  Schlereth, Bernd ^a   Kleindienst, Petra ^a   Fichtner, Iduna ^b   Lorenczewski, Grit ^a   Brischwein, Klaus ^a   Lippold, Sandra ^a   Da Silva, Antonio ^a   Locher, Mathias ^a   Kischel, Roman ^a   Lutterbüse, Ralf ^a   Kufer, Peter ^a   Baeuerle, Patrick A ^a  

^a MICROMET AG   (Germany)

^b Experimental Pharmacology and Oncology GmbH   (Germany)

Author keywords

Bispecific antibody; Ep CAM; T lymphocyte; Tumor immunity; Xenograft model

Indexed keywords

BISPECIFIC ANTIBODY; CD3 ANTIGEN; EPITHELIAL CELL ADHESION MOLECULE; MONOCLONAL ANTIBODY 2C11X4 7; MONOCLONAL ANTIBODY CD3; MONOCLONAL ANTIBODY DIL2KX4 7; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER LOCALIZATION; CANCER MODEL; CONTROLLED STUDY; DISSEMINATED CANCER; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; HUMAN; HUMAN CELL; IMMUNOCOMPETENCE; INOCULATION; LUNG TUMOR; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL; TUMOR GROWTH;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODY SPECIFICITY; ANTIGENS, CD3; ANTIGENS, NEOPLASM; CELL ADHESION MOLECULES; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; IMMUNOCOMPETENCE; IMMUNOTHERAPY; LEUKEMIA, PRE-B-CELL; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, INBRED NOD; MICE, SCID; NEOPLASM TRANSPLANTATION; RECOMBINANT FUSION PROTEINS; SUBCUTANEOUS TISSUE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 28744455481     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-005-0082-x     Document Type: Article

References (37)

1. Perez P, Hoffman RW, Shaw S, Bluestone JA, Segal DM (1985) Specific targeting of cytotoxic T cells by anti-T3 linked to antitarget cell antibody. Nature 316:354-356
2. Staerz UD, Kanagawa O, Bevan MJ (1985) Hybrid antibodies can target sites for attack by T cells. Nature 314:628-631
3. Kufer P, Lutterbuse R, Baeuerle PA (2004) A Revival of bispecific antibodies. Trends Biotechnol 22:238-244
4. Talac R, Nelson H (2000) Current perspectives of bispecific antibody-based immunotherapy. J Biol Regul Homeost Agents 14:175-181
5. Baeuerle PA, Kufer P, Lutterbuse R (2003) Bispecific antibodies for polyclonal T-cell engagement. Curr Opin Mol Ther 5:413-419
6. Dreier T, Lorenczewski G, Brandl C, Hoffmann P, Syring U, Hanakam F, Kufer P, Riethmuller G, Bargou R, Baeuerle PA (2002) Extremely potent rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int J Cancer 100:690-697
7. Dreier T, Baeuerle PA, Fichtner I, Grun M, Schlereth B, Lorenczewski G, Kufer P, Lutterbuse R, Riethmuller G, Gjorstrup P, Bargou RC (2003) T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3- bispecific single-chain antibody construct. J Immunol 170:4397-4402
8. Loffler A, Kufer P, Lutterbuse R, Zettl F, Daniel PT, Schwenkenbecher JM, Riethmuller G, Dorken B, Bargou RCA (2000) recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood 95:2098-2103
9. Loffler A, Gruen M, Wuchter C, Schriever F, Kufer P, Dreier T, Hanakam F, Baeuerle PA, Bommert K, Karawajew L, Dorken B, Bargou RC (2003) Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct. Leukemia 17:900-909
10. Zocher M, Baeuerle PA (2004) Bispecific single-chain antibody fusion protein for targeted depletion of autoreactive B cells via unstimulated human T lymphocytes. Mol Immunol 41:511-518
11. Hoffmann P, Hofmeister R, Brischwein K, Brandl C, Crommer S, Bargou R, Itin C, Prang N, Baeuerle PA (2005) Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. Int J Cancer
12. Offner S, Romaniuk A, Kufer P, Baeuerle PA (2005) Induction of Regular Cytolytic T Cell Synapses by Bispecific Single-Chain Antibody Constructs on MHC Class I-negative Tumor Cells. Mol Immunol
13. Schlereth B, I Fichtner I, Lorenczewski G, Kleindienst P, Brischwein K, da Silva A, Kufer P, Lutterbuese R, Junghahn I, Kasimir-Bauer S, Wimberger P, Kimmig R, Baeuerle PA (2005) Eradication of Tumors from a Human Colon Cancer Cell Line and from Ovarian Cancer Metastases in Immunodeficient Mice by a Single-chain Ep-CAM-/CD3-bispecific Antibody Construct. Cancer Res
14. Went PT, Lugli A, Meier S, Bundi M, Mirlacher M, Sauter G, Dirnhofer S (2004) Frequent EpCam protein expression in human carcinomas. Hum Pathol 35:122-128
15. Litvinov SV, Velders MP, Bakker HA, Fleuren GJ, Warnaar SO (1994) Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule. J Cell Biol 125:437-446
16. Schmitt M, Schmitt A, Reinhardt P, Thess B, Manfras B, Lindhofer H, Riechelmann H, Wiesneth M, Gronau S (2004) Opsonization with a trifunctional bispecific (alphaCD3 x alphaEpCAM) antibody results in efficient lysis in vitro and in - vivo of EpCAM positive tumor cells by cytotoxic T lymphocytes. Int J Oncol 25:841-848
17. Di Paolo C, Willuda J, Kubetzko S, Lauffer I, Tschudi D, Waibel R, Pluckthun A, Stahel RA, Zangemeister-Wittke U (2003) A recombinant immunotoxin derived from a humanized epithelial cell adhesion molecule-specific single-chain antibody fragment has potent and selective antitumor activity. Clin Cancer Res 9:2837-2848
18. Adkins JC, Spencer CM (1998) Edrecolomab (monoclonal antibody 17-1A). Drugs 56:619-626; discussion 627-618
19. de Bono JS, Tolcher AW, Forero A, Vanhove GF, Takimoto C, Bauer RJ, Hammond LA, Patnaik A, White ML, Shen S, Khazaeli MB, Rowinsky EK, LoBuglio AF (2004) ING-1, a monoclonal antibody targeting Ep-CAM in patients with advanced adenocarcinomas. Clin Cancer Res 10:7555-7565
20. Naundorf S, Preithner S, Mayer P, Lippold S, Wolf A, Hanakam F, Fichtner I, Kufer P, Raum T, Riethmuller G, Baeuerle PA, Dreier T (2002) In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment. Int J Cancer 100:101-110
21. Poncelet P, Carayon P (1985) Cytofluorometric quantification of cell-surface antigens by indirect immunofluorescence using monoclonal antibodies. J Immunol Methods 85:65-74
22. Porwit-MacDonald A, Janossy G, Ivory K, Swirsky D, Peters R, Wheatley K, Walker H, Turker A, Goldstone AH, Burnett A (1996) Leukemia-associated changes identified by quantitative flow cytometry IV CD34 overexpression in acute myelogenous leukemia M2 with t(8;21). Blood 87:1162-1169
23. Kufer P, Zettl F, Borschert K, Lutterbuse R, Kischel R, Riethmuller G (2001) Minimal costimulatory requirements for T cell priming and TH1 differentiation: activation of naive human T lymphocytes by tumor cells armed with bifunctional antibody constructs. Cancer Immun 1:10
24. Leo O, Foo M, Sachs DH, Samelson LE, Bluestone JA (1987) Identification of a monoclonal antibody specific for a murine T3 polypeptide. Proc Natl Acad Sci USA 84:1374-1378
25. Mack M, Riethmuller G, Kufer PA (1995) small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc Natl Acad Sci USA 92:7021-7025
26. Sambrook J, Russel DW (2001) Molecular Cloning, a laboratory manual, 3rd edn. Cold Spring Habor Laboratory Press, New York
27. Kaufman RJ (1990) Selection and coamplification of heterologous genes in mammalian cells. Methods Enzymol 185:537-566
28. Brischwein K, Schlereth B, Guller B, Steiger C, Wolf A, Lutterbuese R, Offner S, Locher M, Urbig T, Raum T, Kleindienst P, Wimberger P, Kimmig R, Fichtner I, Kufer P, da Silva A, Baeuerle PA (2005) MT110: A Novel Bispecific Single-chain Antibody Construct with High Efficacy in Eradicating Established Tumors. Mol Immunol
29. Balch CM, Riley LB, Bae YJ, Salmeron MA, Platsoucas CD, von Eschenbach A, Itoh K (1990) Patterns of human tumor-infiltrating lymphocytes in 120 human cancers. Arch Surg 125:200-205
30. Prang N, Preithner S, Brischwein K, Goster P, Woppel A, Muller J, Steiger C, Peters M, Baeuerle PA, da Silva AJ (2005) Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines. Br J Cancer 92:342-349
31. Brissinck J, Demanet C, Moser M, Leo O, Thielemans K (1991) Treatment of mice bearing BCL1 lymphoma with bispecific antibodies. J Immunol 147:4019-4026
32. Demanet C, Brissinck J, Van Mechelen M, Leo O, Thielemans K (1991) Treatment of murine B cell lymphoma with bispecific monoclonal antibodies (anti-idiotype x anti-CD3). J Immunol 147:1091-1097
33. Moreno MB, Titus JA, Cole MS, Tso JY, Le N, Paik CH, Bakacs T, Zacharchuk CM, Segal DM, Wunderlich JR (1995) Bispecific antibodies retarget murine T cell cytotoxicity against syngeneic breast cancer in vitro and in vivo. Cancer Immunol Immunother 40:182-190
34. Penna C, Dean PA, Nelson H (1994) Antitumor x anti-CD3 bifunctional antibodies redirect T-cells activated in vivo with staphylococcal enterotoxin B to neutralize pulmonary metastases. Cancer Res 54:2738-2743
35. Bakacs T, Lee J, Moreno MB, Zacharchuk CM, Cole MS, Tso JY, Paik CH, Ward JM, Segal DMA (1995)bispecific antibody prolongs survival in mice bearing lung metastases of syngeneic mammary adenocarcinoma. Int Immunol 7:947-955
36. Grosse-Hovest L, Brandl M, Dohlsten M, Kalland T, Wilmanns W, Jung G (1999) Tumor-growth inhibition with bispecific antibody fragments in a syngeneic mouse melanoma model: the role of targeted T-cell co-stimulation via CD28. Int J Cancer 80:138-144
37. Ruf P, Lindhofer H (2001) Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood 98:2526-2534